United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Bank of Montreal Can

Bank of Montreal Can reduced its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 38,013 shares of the biotechnology company's stock after selling 4,935 shares during the period. Bank of Montreal Can owned about 0.09% of United Therapeutics worth $13,629,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. LSV Asset Management increased its stake in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Assetmark Inc. increased its stake in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after acquiring an additional 152,249 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock worth $178,972,000 after acquiring an additional 92,240 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of United Therapeutics by 49.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company's stock worth $88,089,000 after acquiring an additional 91,597 shares during the last quarter. Finally, Candriam S.C.A. grew its holdings in United Therapeutics by 2,094.3% in the second quarter. Candriam S.C.A. now owns 64,513 shares of the biotechnology company's stock valued at $20,550,000 after purchasing an additional 61,573 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on UTHR. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. Jefferies Financial Group boosted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a report on Tuesday, August 20th. Finally, Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Trading Down 2.0 %

UTHR stock traded down $7.64 during trading on Friday, reaching $370.49. The stock had a trading volume of 211,330 shares, compared to its average volume of 339,426. The firm has a fifty day moving average price of $367.77 and a 200 day moving average price of $335.65. The company has a market capitalization of $16.54 billion, a P/E ratio of 16.27, a PEG ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the prior year, the business posted $5.38 earnings per share. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 15,000 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 127,227 shares of company stock valued at $47,398,820. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.